Valsts: Amerikas Savienotās Valstis
Valoda: angļu
Klimata pārmaiņas: NLM (National Library of Medicine)
IBUPROFEN LYSINE (UNII: N01ORX9D6S) (IBUPROFEN - UNII:WK2XYI10QM)
Prasco Laboratories
IBUPROFEN LYSINE
IBUPROFEN 10 mg in 1 mL
INTRAVENOUS
PRESCRIPTION DRUG
Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. Ibuprofen Lysine is contraindicated in: - Preterm infants with proven or suspected infection that is untreated; - Preterm infants with congenital heart disease in whom patency of the PDA is necessary for satisfactory pulmonary or systemic blood flow (e.g., pulmonary atresia, severe tetralogy of Fallot, severe coarctation of the aorta); - Preterm infants who are bleeding, especially those with active intracranial hemorrhage or gastrointestinal bleeding; - Preterm infants with thrombocytopenia; - Preterm infants with coagulation defects; - Preterm infants with or who are suspected of having necrotizing enterocolitis; - Preterm infants with significant impairment of renal function. Safety and effectiveness have only been established in premature infants.
How Supplied Ibuprofen Lysine Injection is dispensed in treated1 clear glass single-use vials, each containing 2 mL of sterile solution (NDC 66993-490-84). The solution is not buffered and contains no preservatives. Each milliliter contains 17.1 mg/mL (±)-ibuprofen L-lysine [equivalent to 10 mg/mL (±)-ibuprofen] dissolved in Water for Injection, USP. Ibuprofen Lysine is supplied in a carton (NDC 66993-490-36) containing 3 single-use vials. Storage and Handling Store at 20 – 25°C (68 – 77°F); excursions permitted 15 – 30°C (59 – 86°F) [see USP Controlled Room Temperature]. Protect from light. Store vials in carton until contents have been used.
New Drug Application Authorized Generic
IBUPROFEN LYSINE- IBUPROFEN LYSINE SOLUTION PRASCO LABORATORIES ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE IBUPROFEN LYSINE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR IBUPROFEN LYSINE. IBUPROFEN LYSINE INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 1974 RECENT MAJOR CHANGES Warnings and Precautions (5.6) 10/2023 INDICATIONS AND USAGE Ibuprofen Lysine is a nonsteroidal anti-inflammatory drug indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA. (1) DOSAGE AND ADMINISTRATION A course of therapy is three doses administered I.V. (2.1) An initial dose of 10 mg/kg (based on birth weight) is followed by two doses of 5 mg/kg each, after 24 and 48 hours (2.1) Do not administer if anuria or marked oliguria (<0.6 mL/kg/hr) is evident at the scheduled time of the second or third dose (2.1) DOSAGE FORMS AND STRENGTHS 20 mg/2 mL (10 mg/mL) as a clear sterile preservative-free solution of the L-lysine salt of ibuprofen in a 2 mL single-use vial (3) CONTRAINDICATIONS Ibuprofen Lysine is contraindicated in preterm infants: With proven or suspected infection that is untreated (4) With congenital heart disease in whom patency of the PDA is necessary for satisfactory pulmonary or systemic blood flow (4) With impaired renal function (4) With thrombocytopenia, coagulation defects or who are bleeding (4) With or who are suspected of having necrotizing enterocolitis (4) WARNINGS AND PRECAUTIONS Ibuprofen Lysine has not been assessed for neurodevelopmental outcome and growth (5.1) Ibuprofen Lysine may alter the usual signs Izlasiet visu dokumentu